Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
Alicia M BlessingJanice M Santiago-O'FarrillWeiqun MaoLan PangJing NingDaewoo PakLakshmi Reddy BolluPhilip RaskLaKesla IlesHailing YangSamantha TranEzzeddine ElmirGeoffrey BartholomeuszRobert LangleyZhen LuRobert C BastPublished in: Cancer (2020)
Crizotinib may eliminate dormant, autophagic, drug-resistant OvCa cells that remain after conventional cytoreductive surgery and combination chemotherapy. A clinical trial of ALK inhibitors as maintenance therapy after second-look operations should be seriously considered.
Keyphrases
- drug resistant
- cell death
- cell cycle arrest
- clinical trial
- multidrug resistant
- acinetobacter baumannii
- induced apoptosis
- advanced non small cell lung cancer
- minimally invasive
- coronary artery bypass
- diffuse large b cell lymphoma
- phase ii
- open label
- protein kinase
- locally advanced
- signaling pathway
- endoplasmic reticulum stress
- study protocol
- tyrosine kinase
- radiation therapy
- stem cells
- double blind
- randomized controlled trial
- surgical site infection
- phase iii
- mesenchymal stem cells
- rectal cancer
- atrial fibrillation
- coronary artery disease
- pi k akt
- cell therapy
- percutaneous coronary intervention